Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00071240 · ClinicalTrials.gov registry record · Phase 2
Growth Hormone to Increase Immune Function in People With HIV
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00071240 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 22 participants.
The verdict
NCT00071240, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
Growth hormone plays an important role in the development of the immune system. Studies suggest that growth hormone may promote growth of the thymus, a gland responsible for the production of important immune cells called T cells. Since these cells are lost during the course of HIV infection, it is possible that growth hormone treatment could help restore the immune system. This study will determine whether the administration of growth hormone can increase the size and function of the thymus and cause an increase in the number of new T cells in the blood of people infected with HIV. Study hypothesis: Growth hormone treatment will enhance T cell production in HIV infected adults.
Interventions
- DRUG Somatropin (recombinant human growth hormone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2002-10 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00071240
The ClinicalTrials.gov registry entry for NCT00071240 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Somatropin (recombinant human growth hormone) is the first listed.
NCT00071240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00071240 about?
NCT00071240 is a clinical study titled "Growth Hormone to Increase Immune Function in People With HIV". Growth hormone plays an important role in the development of the immune system. Studies suggest that growth hormone may promote growth of the thymus, a gland responsible for the production of important immune cells called T cells. Since these cells are lost during the course of HIV infection, it is ...
What is the current status of trial NCT00071240?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2002-10. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00071240?
The interventions under investigation include: Somatropin (recombinant human growth hormone) (DRUG).
Who is sponsoring clinical trial NCT00071240?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.